Zoladex
CYP2D6 Polymorphism
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CYP2D6 Polymorphism cohort.
Same molecule, other indications
Zoladex is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →